It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bile acid synthesis plays a key role in regulating whole body cholesterol homeostasis. Transcriptional factor EB (TFEB) is a nutrient and stress-sensing transcriptional factor that promotes lysosomal biogenesis. Here we report a role of TFEB in regulating hepatic bile acid synthesis. We show that TFEB induces cholesterol 7α-hydroxylase (CYP7A1) in human hepatocytes and mouse livers and prevents hepatic cholesterol accumulation and hypercholesterolemia in Western diet-fed mice. Furthermore, we find that cholesterol-induced lysosomal stress feed-forward activates TFEB via promoting TFEB nuclear translocation, while bile acid-induced fibroblast growth factor 19 (FGF19), acting via mTOR/ERK signaling and TFEB phosphorylation, feedback inhibits TFEB nuclear translocation in hepatocytes. Consistently, blocking intestinal bile acid uptake by an apical sodium-bile acid transporter (ASBT) inhibitor decreases ileal FGF15, enhances hepatic TFEB nuclear localization and improves cholesterol homeostasis in Western diet-fed mice. This study has identified a TFEB-mediated gut-liver signaling axis that regulates hepatic cholesterol and bile acid homeostasis.
TFEB is a transcriptional regulator of lysosomal biogenesis, activated upon starvation or lysosomal stress. Here the authors report that TFEB regulates hepatic bile acid synthesis downstream of FGF19 signaling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375)
2 University of Kansas Medical Center, Department of Molecular and Integrative Physiology, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375)
3 Baylor College of Medicine, Department of Molecular and Cellular Biology, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
4 University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375); University of Oklahoma Health Sciences Center, Harold Hamm Diabetes Center, Department of Physiology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618)
5 Sekisui XenoTech LLC, Kansas City, USA (GRID:grid.422828.6) (ISNI:0000 0004 1798 670X)
6 University of Oklahoma Health Sciences Center, Harold Hamm Diabetes Center, Department of Physiology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618)